ZA200203342B - Method for diagnosing a transmissible spongiform subacute encephalopathy caused by an unconventional transmissible agent strain in a biological sample. - Google Patents
Method for diagnosing a transmissible spongiform subacute encephalopathy caused by an unconventional transmissible agent strain in a biological sample. Download PDFInfo
- Publication number
- ZA200203342B ZA200203342B ZA200203342A ZA200203342A ZA200203342B ZA 200203342 B ZA200203342 B ZA 200203342B ZA 200203342 A ZA200203342 A ZA 200203342A ZA 200203342 A ZA200203342 A ZA 200203342A ZA 200203342 B ZA200203342 B ZA 200203342B
- Authority
- ZA
- South Africa
- Prior art keywords
- prp
- res
- proteinase
- sample
- strain
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 57
- 239000012472 biological sample Substances 0.000 title claims description 16
- 208000014644 Brain disease Diseases 0.000 title description 4
- 208000032274 Encephalopathy Diseases 0.000 title description 4
- 108010067770 Endopeptidase K Proteins 0.000 claims description 79
- 108010007288 PrPSc Proteins Proteins 0.000 claims description 58
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 44
- 108700004121 sarkosyl Proteins 0.000 claims description 44
- 229940016590 sarkosyl Drugs 0.000 claims description 42
- 239000000872 buffer Substances 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000004202 carbamide Substances 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 238000003748 differential diagnosis Methods 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 11
- 239000004365 Protease Substances 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 230000003196 chaotropic effect Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 7
- 235000019419 proteases Nutrition 0.000 claims description 7
- 239000002563 ionic surfactant Substances 0.000 claims description 6
- 239000011539 homogenization buffer Substances 0.000 claims description 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 4
- 229920004890 Triton X-100 Polymers 0.000 claims description 4
- 239000003945 anionic surfactant Substances 0.000 claims description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 4
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920004929 Triton X-114 Polymers 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 2
- IFUVSXLHBNRDSK-UHFFFAOYSA-N 1-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]tetradecan-2-ol Chemical compound CCCCCCCCCCCCC(O)COCCOCCOCCOCCOCCOCCOCCO IFUVSXLHBNRDSK-UHFFFAOYSA-N 0.000 claims 1
- 108010064571 PrPC Proteins Proteins 0.000 claims 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 36
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 31
- 238000001514 detection method Methods 0.000 description 24
- 208000008864 scrapie Diseases 0.000 description 20
- 241001494479 Pecora Species 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 12
- 238000013198 immunometric assay Methods 0.000 description 12
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 11
- 241000282412 Homo Species 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000012440 Acetylcholinesterase Human genes 0.000 description 7
- 108010022752 Acetylcholinesterase Proteins 0.000 description 7
- 108091000054 Prion Proteins 0.000 description 7
- 102000029797 Prion Human genes 0.000 description 7
- 229940022698 acetylcholinesterase Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000005497 microtitration Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000002704 Sporadic Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- -1 dodecyl- Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101710138751 Major prion protein Proteins 0.000 description 1
- 102100025818 Major prion protein Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700021402 PrP 27-30 Proteins 0.000 description 1
- 101100311558 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SWD2 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108010056119 protease So Proteins 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9914242A FR2801106B1 (fr) | 1999-11-12 | 1999-11-12 | Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200203342B true ZA200203342B (en) | 2004-02-11 |
Family
ID=9552058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200203342A ZA200203342B (en) | 1999-11-12 | 2002-04-26 | Method for diagnosing a transmissible spongiform subacute encephalopathy caused by an unconventional transmissible agent strain in a biological sample. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7097997B1 (ja) |
| EP (1) | EP1232395B1 (ja) |
| JP (1) | JP4842478B2 (ja) |
| CN (1) | CN100383529C (ja) |
| AU (1) | AU779688B2 (ja) |
| BG (1) | BG65933B1 (ja) |
| CA (1) | CA2390891C (ja) |
| DE (1) | DE60032932T2 (ja) |
| DZ (1) | DZ3229A1 (ja) |
| ES (1) | ES2280263T3 (ja) |
| FR (1) | FR2801106B1 (ja) |
| HU (1) | HU230068B1 (ja) |
| MA (1) | MA26043A1 (ja) |
| NZ (1) | NZ519210A (ja) |
| PT (1) | PT1232395E (ja) |
| RO (1) | RO121829B1 (ja) |
| WO (1) | WO2001035104A1 (ja) |
| ZA (1) | ZA200203342B (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620629B1 (en) * | 1997-02-21 | 2003-09-16 | The Regents Of The University Of California | Method for detecting prions |
| GB2376071A (en) * | 2001-05-31 | 2002-12-04 | Mini Agriculture & Fisheries | Method for typing a TSE strain |
| FR2842303B1 (fr) * | 2002-07-09 | 2004-09-24 | Commissariat Energie Atomique | Methode de detection automatisable de la prpres et ses applications |
| GB2394663B (en) * | 2002-11-01 | 2006-07-12 | Medical Res Council | Prion decontamination |
| WO2004039418A1 (en) * | 2002-11-01 | 2004-05-13 | Medical Research Council | Prion decontamination |
| US20040192887A1 (en) * | 2003-03-25 | 2004-09-30 | Ralph Zahn | PH-dependent polypeptide aggregation and its use |
| DE10328125A1 (de) * | 2003-06-23 | 2005-01-13 | Roche Diagnostics Gmbh | Nachweis von Protease-resistentem Prion-Protein nach spontaner Transformationsreaktion |
| JP4709149B2 (ja) | 2003-08-13 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | プリオン特異的ペプチド試薬 |
| US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| US7888011B2 (en) * | 2004-10-18 | 2011-02-15 | U.S. Genomics, Inc. | Methods for isolation of nucleic acids from prokaryotic spores |
| AU2006204705C1 (en) * | 2005-01-13 | 2012-07-05 | Novartis Vaccines And Diagnostics, Inc. | ELISA assays using prion-specific peptide reagents |
| EP1848830A4 (en) * | 2005-01-13 | 2009-05-06 | Novartis Vaccines & Diagnostic | ISOLATION OF PATHOGENIC PRIONS |
| WO2006076683A2 (en) * | 2005-01-13 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Isolation and detection of pathogenic prions |
| EP1731911A1 (fr) | 2005-06-07 | 2006-12-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procédé utile pour la détection d'encéphalopathies |
| JP4724816B2 (ja) * | 2005-09-06 | 2011-07-13 | シャープ株式会社 | タンパク質の測定方法 |
| NZ566020A (en) | 2005-09-09 | 2012-08-31 | Novartis Ag | Prion-specific peptoid reagents |
| FR2893952B1 (fr) | 2005-11-25 | 2008-02-22 | Bio Rad Pasteur Sa | Procede d'identification du genotype en position 171 de la proteine prion d'ovin ainsi que trousses de mise en oeuvre de ce procede. |
| JP2010523978A (ja) * | 2007-04-04 | 2010-07-15 | ノバルティス アーゲー | プリオンｅｌｉｓａ |
| JP2010523977A (ja) * | 2007-04-04 | 2010-07-15 | ノバルティス アーゲー | プリオンアッセイ |
| CN102083450A (zh) * | 2008-04-30 | 2011-06-01 | 诺华有限公司 | 致病性构象异构体的分析 |
| US8703416B2 (en) | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
| CN102812118B (zh) | 2010-04-08 | 2016-01-20 | 恰根有限公司 | 分离和纯化核酸的方法 |
| EP2556158B1 (en) | 2010-04-08 | 2019-12-18 | Qiagen GmbH | Chromatographic device and method for isolating and purifying nucleic acids |
| WO2011124708A1 (en) * | 2010-04-08 | 2011-10-13 | Qiagen Gmbh | Method for precipitating anionic surfactant ions in the presence of nucleic acids |
| EP2395082A1 (en) | 2010-06-14 | 2011-12-14 | QIAGEN GmbH | Extraction of nucleic acids from wax-embedded samples |
| WO2012174496A2 (en) * | 2011-06-17 | 2012-12-20 | Somalogic, Inc. | Method for purification and identification of sperm cells |
| EP3149034B1 (en) * | 2014-05-30 | 2022-07-13 | New England Biolabs, Inc. | Deglycosylation reagents and methods |
| KR101866249B1 (ko) * | 2016-11-29 | 2018-06-12 | 박순현 | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733734A (en) * | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5877012A (en) * | 1993-03-25 | 1999-03-02 | Novartis Finance Corporation | Class of proteins for the control of plant pests |
| JP2000512131A (ja) * | 1996-05-29 | 2000-09-19 | マクギル ユニバーシティー | プリオン蛋白結合蛋白およびその使用法 |
| FR2758337B1 (fr) * | 1997-01-14 | 1999-03-05 | Commissariat Energie Atomique | Methode de criblage de substances a action therapeutique dans le traitement des esst comprenant une etape d'isolement de la prpres, a partir de la rate, procede d'isolement de le prpres et ses applications |
| EP0861900A1 (en) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunological detection of prions |
| JPH10267928A (ja) * | 1997-03-28 | 1998-10-09 | Norin Suisansyo Kachiku Eisei Shikenjo | 微量異常プリオン蛋白質もしくはその部分分解断片の検出方法 |
| JPH1132795A (ja) * | 1997-07-18 | 1999-02-09 | Sangi Co Ltd | 病原性プリオン蛋白質の検出方法及びその濃縮方法 |
| FR2774988B1 (fr) * | 1998-02-16 | 2000-05-05 | Commissariat Energie Atomique | Procede de purification de la prpres a partir d'un echantillon biologique et ses applications |
| US6214565B1 (en) * | 1998-10-09 | 2001-04-10 | The Regents Of The University Of California | Assay for disease related conformation of a protein and isolating same |
| US6528269B1 (en) * | 1998-06-22 | 2003-03-04 | Case Western Reserve University | Immunological agents specific for prion protein (PRP) |
| GB2348203B (en) * | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
| FI982481A0 (fi) * | 1998-11-17 | 1998-11-17 | Wallac Oy | Immunomääritys nautaeläinten tarttuvan spongiomuotoisen aivotaudin määrittämiseksi |
| FI982480A0 (fi) * | 1998-11-17 | 1998-11-17 | Wallac Oy | Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi |
-
1999
- 1999-11-12 FR FR9914242A patent/FR2801106B1/fr not_active Expired - Fee Related
-
2000
- 2000-11-13 CA CA2390891A patent/CA2390891C/fr not_active Expired - Lifetime
- 2000-11-13 PT PT00979723T patent/PT1232395E/pt unknown
- 2000-11-13 EP EP00979723A patent/EP1232395B1/fr not_active Expired - Lifetime
- 2000-11-13 ES ES00979723T patent/ES2280263T3/es not_active Expired - Lifetime
- 2000-11-13 JP JP2001536583A patent/JP4842478B2/ja not_active Expired - Lifetime
- 2000-11-13 AU AU17119/01A patent/AU779688B2/en not_active Expired
- 2000-11-13 DE DE60032932T patent/DE60032932T2/de not_active Expired - Lifetime
- 2000-11-13 DZ DZ003229A patent/DZ3229A1/fr active
- 2000-11-13 NZ NZ519210A patent/NZ519210A/en not_active IP Right Cessation
- 2000-11-13 HU HU0203691A patent/HU230068B1/hu unknown
- 2000-11-13 WO PCT/FR2000/003159 patent/WO2001035104A1/fr active IP Right Grant
- 2000-11-13 US US10/129,111 patent/US7097997B1/en not_active Expired - Lifetime
- 2000-11-13 RO ROA200200588A patent/RO121829B1/ro unknown
- 2000-11-13 CN CNB008159955A patent/CN100383529C/zh not_active Expired - Fee Related
-
2002
- 2002-04-26 ZA ZA200203342A patent/ZA200203342B/en unknown
- 2002-05-10 BG BG106686A patent/BG65933B1/bg unknown
- 2002-06-10 MA MA26681A patent/MA26043A1/fr unknown
-
2005
- 2005-09-14 US US11/224,951 patent/US7429463B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2280263T3 (es) | 2007-09-16 |
| DE60032932T2 (de) | 2007-10-25 |
| BG65933B1 (bg) | 2010-05-31 |
| FR2801106B1 (fr) | 2007-10-05 |
| CA2390891A1 (fr) | 2001-05-17 |
| US7097997B1 (en) | 2006-08-29 |
| CN100383529C (zh) | 2008-04-23 |
| RO121829B1 (ro) | 2008-05-30 |
| EP1232395A1 (fr) | 2002-08-21 |
| US20060084130A1 (en) | 2006-04-20 |
| PT1232395E (pt) | 2007-04-30 |
| DZ3229A1 (fr) | 2001-05-17 |
| BG106686A (bg) | 2003-11-28 |
| US7429463B2 (en) | 2008-09-30 |
| EP1232395B1 (fr) | 2007-01-10 |
| DE60032932D1 (de) | 2007-02-22 |
| JP4842478B2 (ja) | 2011-12-21 |
| CA2390891C (fr) | 2012-05-01 |
| FR2801106A1 (fr) | 2001-05-18 |
| MA26043A1 (fr) | 2004-04-01 |
| HUP0203691A2 (hu) | 2003-03-28 |
| AU779688B2 (en) | 2005-02-03 |
| NZ519210A (en) | 2005-03-24 |
| HUP0203691A3 (en) | 2012-09-28 |
| HU230068B1 (hu) | 2015-06-29 |
| AU1711901A (en) | 2001-06-06 |
| WO2001035104A1 (fr) | 2001-05-17 |
| JP2003530541A (ja) | 2003-10-14 |
| CN1391652A (zh) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7429463B2 (en) | Method for diagnosing a transmissible spongiform subacute encephalopathy caused by an unconventional transmissible agent strain in a biological sample | |
| AU765939B2 (en) | Assay for disease related conformation of a protein | |
| JP4422396B2 (ja) | ヒト起源の病原性プリオンを特異的に検出する抗体およびその体を用いて実施される検出方法 | |
| EP1435521B1 (en) | Detection and diagnosis of transmissible spongiform encephalopathies | |
| EP2085404B1 (en) | Peptides for discrimination of prions | |
| US7399603B2 (en) | Antibodies for discrimination of prions | |
| US20080318209A1 (en) | Cjd Prion Testing | |
| MXPA06008396A (en) | Cjd prion testing | |
| AU2004200467A1 (en) | Antibodies for discrimination of prions | |
| MXPA01003626A (en) | Assay for disease related conformation of a protein | |
| AU2003271329A1 (en) | Assay for disease related conformation of a protein |